Lack of consistent approach in IQWiG/G-BA AMNOG-based decisions leaves industry confused about new reimbursement route.
Continue reading "AZ’s Brillinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward" »
There are good-value opportunities in Europe for VCs with money to invest, but those seeking new funds face an unprecedentedly tough challenge that’s compounded by euro uncertainty.
Continue reading "Euro Crisis Hits Investor Risk Appetite, But Opportunities Remain" »
Companies struggle on how even to begin assessing impact of a possible Euro break-up.
Continue reading "The End of The Euro: What Might It Mean For Pharma?" »
Companies struggle on how even to begin assessing impact of a possible Euro break-up.
Continue reading "The End of The Euro: What Might It Mean For Pharma?" »